Rabeprazole Sodium Tablet, Delayed Release
NDC Package 72888-059-30
Package Information
Rabeprazole Sodium tablets is rabeprazole is used to treat certain stomach and esophagus problems (such as acid reflux, ulcers). This formulation utilizes a tablet, delayed release delivery system. Marketed by Advagen Pharma Limited, this product is identified by NDC 72888-059 and is authorized under FDA application ANDA204237.
Identification & Billing
- RxCUI: 854868 - RABEprazole sodium 20 MG Delayed Release Oral Tablet
- RxCUI: 854868 - rabeprazole sodium 20 MG Delayed Release Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 72888 - Advagen Pharma Limited
- 72888-059 - Rabeprazole Sodium
- 72888-059-30 - 30 TABLET, DELAYED RELEASE in 1 BOTTLE
- 72888-059 - Rabeprazole Sodium
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (72888-059). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 72888-059-30 identifies a specific commercial package of 30 tablet, delayed release in 1 bottle of Rabeprazole Sodium, a human prescription drug labeled by Advagen Pharma Limited. This tablet, delayed release is formulated for oral use and contains rabeprazole sodium as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Advagen Pharma Limited on June 01, 2017. The current certification is valid through December 31, 2027.
What are the primary indications for this medication?
Rabeprazole is used to treat certain stomach and esophagus problems (such as acid reflux, ulcers). It works by decreasing the amount of acid your stomach makes. It relieves symptoms such as heartburn, difficulty swallowing, and persistent cough. This medication helps heal acid damage to the stomach and esophagus, helps prevent ulcers, and may help prevent cancer of the esophagus. Rabeprazole belongs to a class of drugs known as proton pump inhibitors (PPIs).
How is this Advagen Pharma Limited product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 72888005930. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 30 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.